Roswell Park at ASCO

Saturday, May 30, 2026

• Michael Wong, MD presenting author, Abstract 9518 - A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.
  • 4:30 p.m.

• Jayasree Krishnan, MD, MSPH, (PGY 4 Hematology Oncology Fellow), first author, presenting publication 7541 - CAR-T in the older adults: Real-world survival and toxicity in patients ≥ 75 years with relapsed/refractory multiple myeloma.
   
• Fayaz Khan, first author, presenting - Prophylactic vs reactive PEG tube placement in early-stage head and neck (H&N) cancer treated with curative-intent radiotherapy: Balancing benefit and burden in real-world practice.
  • 2026 Conquer Cancer Merit Award Winner
     
• Fayaz Khan, first author, presenting - Pre-lymphodepletion CRP and ferritin risk stratification as a predictor of early immune toxicities and hematologic complications after CAR-T therapy: A propensity-matched cohort study.
   
• Vaishali Deenadayalan, MBBS, (PGY 3 Hematology Oncology Fellow), first author, presenting abstract 1135 - Impact of protein–energy malnutrition on outcomes of metastatic triple-negative breast cancer patients receiving chemotherapy: A real-world analysis.
  • 2026 Conquer Cancer Merit Award Winner
     
• Zunairah Shah, MBBS, first author, presenting - Real-world brain metastasis outcomes with T-DXd versus tucatinib-based therapy in second-line HER2-positive metastatic breast cancer.
  • 2026 Conquer Cancer Merit Award Winner
     
• Zunairah Shah, MBBS, first author, presenting - GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.
   
• Zunairah Shah, MBBS, first author, presenting - Real-world cardiotoxicity with HER2 antibody–drug conjugates and survival after treatment continuation.
   
• Mariam Haji Ahmad, MBBCh, (PGY 3 Hematology Oncology Fellow), first author, presenting - Standardized exam-style benchmarking of large language models in breast cancer clinical decision-making.
   

Eunice Wang, MD, is the invited speaker for the educational session New Drugs in Oncology: Incorporation Into Practice.

• Friday, May 29, 2026 2:45-4:15 p.m.
• Presenting Ziftomenib and Revumenib for Relapsed or Refractory Acute Myeloid Leukemia